	US 12,454,580 B2
	FRB antibodies
Alexander Astrakhan, Seattle, WA (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Appl. No. 17/917,418
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
PCT Filed Apr. 9, 2021, PCT No. PCT/US2021/026597 § 371(c)(1), (2) Date Oct. 6, 2022, PCT Pub. No. WO2021/207613, PCT Pub. Date Oct. 14, 2021.
Claims priority of provisional application 63/007,990, filed on Apr. 10, 2020.
Prior Publication US 2023/0151117 A1, May 18, 2023
Int. Cl. C07K 16/40 (2006.01)

CPC C07K 16/40 (2013.01) [C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2319/60 (2013.01)]

20 Claims

1. An anti-FKBP Rapamycin binding (FRB) antibody or antigen binding fragment thereof that binds an FRB polypeptide, wherein the antibody or antigen binding fragment thereof comprises a light chain variable region comprising the light chain CDRs (CDRL1-CDRL3) set forth in any one of SEQ ID NOs: 1-3, 11-13, 21-23, 31-33, and 41-43 and a heavy chain variable region comprising the heavy chain CDRs (CDRH1-CDRH3) set forth in any one of SEQ ID NOs: 4-6, 14-16, 24-26, 34-36, and 44-46.